Invitation to Meeting and Conference Call for Clavis Pharma's $380
Million Partnering Agreement
(Thomson Reuters ONE) - Oslo, Norway, 24 November 2009Clavis Pharma ASA (OSE: CLAVIS), the clinical stage oncology focusedpharmaceutical company, announced today a $380 million agreement forthe further development and commercialisation of its drug candidate,CP-4126, currently in Phase II development in pancreatic cancer.A meeting for investors, analysts and press will take place in Osloat 10.00 CET today, 24 November 2009 at Hotel Continental,Stortingsgaten 24, Oslo, Norway.An international conference call will take place at 12:00 CET -details are given below.Access the audio for the meeting by dialling the following andquoting confirmation code 4956336 :+47 2415 9758 (from Norway)+44 (0)20 7806 1966 (International)For visuals click on the direct access link:http://www.livemeeting.com/cc/premconfeurope/join?id=4956336&role=attend&pw=pw6623Participating in the Meeting and Conference Call will be:Geir Christian Melen, CEO, Clavis Pharma ASAKeith McCullagh, Chairman, Clavis Pharma ASAPatrick Mahaffy, President & CEO, Clovis Oncology Inc.The presentation will be made available on www.clavispharma.com inthe Investors section from 09:00 CET. A webcast of the conferencecall will be available from Clavis Pharma's website,www.clavispharma.com for a period of 30 days.For Further Information Contact:Geir Christian MelenChief Executive Officer+47 24 11 09 50+47 91 30 29 65 (mob)geir.christian.melen(at)clavispharma.comGunnar ManumChief Financial Officer+47 24 11 09 71+47 95 17 91 90 (mob)gunnar.manum(at)clavispharma.comMark Swallow / Nina Enegren / David DibleCitigate Dewe Rogerson+44 207 282 2948clavispharma(at)citigatedr.co.ukThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 24.11.2009 - 07:11 Uhr
Sprache: Deutsch
News-ID 8757
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 261 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Invitation to Meeting and Conference Call for Clavis Pharma's $380
Million Partnering Agreement"
steht unter der journalistisch-redaktionellen Verantwortung von
Clavis Pharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
